FINWIRES · TerminalLIVE
FINWIRES

TVS Srichakra's Consolidated Profit Surges in Fiscal Q4; Shares Jump 12%

By

TVS Srichakra's (NSE:TVSSRICHAK, BOM:509243) consolidated attributable profit shot up to 360.9 million Indian rupees from 95.9 million rupees a year ago.

Earnings per share came in at 47.13 rupees from 12.52 rupees a year earlier, the tire manufacturer said in a filing to the Indian stock exchanges on Wednesday.

Revenue from operations in fiscal Q4 also rose to 9.81 billion rupees from 8.18 billion rupees a year ago.

The company's board recommended a final dividend of 37.80 rupees per share on the face value of 10 rupees per share for the financial year 2025-26.

TVS' shares shot up 12% in recent trade.

Related Articles

Asia

Suning.com's Executives to Raise Stake in Company

Suning.com's (SHE:002024) executives plan to increase their holdings in the company by no less than 6 million yuan, according to a Wednesday disclosure on the Shenzhen bourse.The executives, including Chairman Ren Jun, will raise their stake through centralized bidding from Wednesday, May 27 until Aug. 26.The Chinese retailer's shares jumped 5% at the close.

$SHE:002024
Asia

Market Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says

The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) Therapeutics (HKG:2126) CEO Leo Tian."For us, everything is business as ​usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly ⁠dependent on international cooperation," Reuters quoted Tian as saying.JW is "actively seeking cooperation" with companies outside China for assets in its pipeline, the report said, citing Tian.Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^SSEC$^SZSE$HKG:2126
Asia

Tokyo Kiraboshi Financial Group to Receive 8 Billion Yen Dividend from Subsidiary for UI Bank Capital Increase

Tokyo Kiraboshi Financial Group (TYO:7173) will receive a dividend of 8 billion yen from its consolidated subsidiary, Kiraboshi Bank, on June 1, to help fund a capital increase of UI Bank.The dividend will be recorded as operating income in the company's non-consolidated financial statements for the fiscal year ending March 31, 2027, according to a Tokyo bourse filing on Wednesday.However, because the dividend originates from a consolidated subsidiary, it will have no impact on the Group's consolidated financial results for the same period.The disclosure was made as the event requires submission of an extraordinary report under Japan's Financial Instruments and Exchange Act.

$TYO:7173